tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Keros Therapeutics Begins Phase 3 Trial for Elritercept

Story Highlights
Keros Therapeutics Begins Phase 3 Trial for Elritercept

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Keros Therapeutics ( (KROS) ) has provided an update.

On July 17, 2025, Keros Therapeutics announced the dosing of the first patient in the Phase 3 RENEW clinical trial of elritercept for adults with transfusion-dependent anemia and myelodysplastic syndromes. This milestone activates a $10 million payment from Takeda Pharmaceuticals under their global license agreement, highlighting Keros’ progress in developing elritercept as a potentially differentiated therapy for MDS patients. The trial aims to evaluate elritercept’s efficacy in reducing red blood cell transfusions, with Keros eligible for further milestone payments and royalties, potentially exceeding $1.1 billion.

The most recent analyst rating on (KROS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Spark’s Take on KROS Stock

According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.

The overall score reflects significant challenges in profitability and strategic direction, as evidenced by the workforce reduction and halted drug project. Technical indicators show neutral momentum, while the financial performance is under pressure despite a strong balance sheet.

To see Spark’s full report on KROS stock, click here.

More about Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The company is a leader in understanding the role of TGF-ß proteins, which regulate the growth, repair, and maintenance of various tissues, including blood, bone, and muscle. Keros’ lead product candidate, KER-065, targets neuromuscular diseases, while its most advanced candidate, elritercept (KER-050), is developed for treating cytopenias in myelodysplastic syndrome and myelofibrosis patients.

Average Trading Volume: 685,848

Technical Sentiment Signal: Sell

Current Market Cap: $578.8M

For an in-depth examination of KROS stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1